In shock move, EU panel rejects Alzheimer's drug Leqembi
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Health Innovators - Steve Damon
Steven Damon, Micron Biomedical, BIO 2024, microneedles,
Third Arc's $165m for T cell engagers, plus other bio rounds
This week's round-up of new financings in the biotech world is headed by a big round for Third Arc, a specialist in T-cell engager antibodies, with Autobahn, Brenig, Confo, and GRO Bio also
Creative review: The Cannes Lions trends that pharma needs t...
Pharma creative needs to stand up and be counted.
AZ joins call for new UK PM to back Oxford-Cambridge hub
In a letter to the new UK Prime Minister Keir Starmer, leading figures in industry and academia have called for a plan to turn the Oxford-Cambridge region into the 'crown jewel' of the nati
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
Novo Nordisk seeks to target heart disease with Cardior acqu...
Cardior CSO will speak at the Oligonucleotide Therapeutics and Delivery conference following announcement of a buyout by Novo Nordisk to enhance their
6th Inflammasome Therapeutics Summit
In the rapidly evolving field of inflammasome therapeutics, the need for innovative approaches to overcome the preclinical and clinical hurdles is more critical than ever.
2nd Covalent Drug Discovery & Development Summit
Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology, Immunology & B
7th TPD & Induced Proximity Summit
Fast-Track Discovery, Development & Approval of Selective, Safe & Clinically Relevant TACs & Glues for Degradation, Stabilization, & Phosphorylation to Successfully Address
5th Gene Therapy Immunogenicity Summit
Optimise Safety & De-Risk Efficacy of Viral Vector Based Gene Therapies